165 related articles for article (PubMed ID: 38674389)
21. Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus.
Lavrado NC; Salles GF; Cardoso CRL; de França PHC; Melo MFDGG; Leite NC; Villela-Nogueira CA
Liver Int; 2024 Apr; 44(4):1042-1050. PubMed ID: 38293718
[TBL] [Abstract][Full Text] [Related]
22. Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey.
Hernaez R; McLean J; Lazo M; Brancati FL; Hirschhorn JN; Borecki IB; Harris TB; ; Nguyen T; Kamel IR; Bonekamp S; Eberhardt MS; Clark JM; Kao WH; Speliotes EK
Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1183-1190.e2. PubMed ID: 23416328
[TBL] [Abstract][Full Text] [Related]
23. Role of candidate gene variants in modulating the risk and severity of alcoholic hepatitis.
Beaudoin JJ; Liang T; Tang Q; Banini BA; Shah VH; Sanyal AJ; Chalasani NP; Gawrieh S
Alcohol Clin Exp Res; 2021 Apr; 45(4):709-719. PubMed ID: 33616244
[TBL] [Abstract][Full Text] [Related]
24. Genetic variants associated with metabolic dysfunction-associated fatty liver disease in western China.
Liao S; An K; Liu Z; He H; An Z; Su Q; Li S
J Clin Lab Anal; 2022 Sep; 36(9):e24626. PubMed ID: 35881683
[TBL] [Abstract][Full Text] [Related]
25. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
26. The Protection Conferred by HSD17B13 rs72613567 Polymorphism on Risk of Steatohepatitis and Fibrosis May Be Limited to Selected Subgroups of Patients With NAFLD.
Vilar-Gomez E; Pirola CJ; Sookoian S; Wilson LA; Liang T; Chalasani N
Clin Transl Gastroenterol; 2021 Sep; 12(9):e00400. PubMed ID: 34506332
[TBL] [Abstract][Full Text] [Related]
27. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals.
Lin YC; Chang PF; Chang MH; Ni YH
Am J Clin Nutr; 2014 Apr; 99(4):869-74. PubMed ID: 24477042
[TBL] [Abstract][Full Text] [Related]
28. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients.
Enomoto H; Aizawa N; Hasegawa K; Ikeda N; Sakai Y; Yoh K; Takata R; Yuri Y; Kishino K; Shimono Y; Ishii N; Takashima T; Nishimura T; Nishikawa H; Iwata Y; Iijima H; Nishiguchi S
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349377
[TBL] [Abstract][Full Text] [Related]
29. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
[TBL] [Abstract][Full Text] [Related]
30.
Kalinowski P; Smyk W; Nowosad M; Paluszkiewicz R; Michałowski Ł; Ziarkiewicz-Wróblewska B; Weber SN; Milkiewicz P; Lammert F; Zieniewicz K; Krawczyk M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555467
[TBL] [Abstract][Full Text] [Related]
31. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.
Koo BK; Joo SK; Kim D; Bae JM; Park JH; Kim JH; Kim W
J Gastroenterol Hepatol; 2018 Jun; 33(6):1277-1285. PubMed ID: 29193269
[TBL] [Abstract][Full Text] [Related]
32. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of hepatocellular carcinoma in alcoholic cirrhosis.
Falleti E; Cussigh A; Cmet S; Fabris C; Toniutto P
Dig Liver Dis; 2016 Jan; 48(1):69-75. PubMed ID: 26493626
[TBL] [Abstract][Full Text] [Related]
33. PNPLA3 is the dominant SNP linked to liver disease severity at time of first referral to a tertiary center.
Balcar L; Semmler G; Oberkofler H; Zandanell S; Strasser M; Datz L; Niederseer D; Feldman A; Stickel F; Datz C; Paulweber B; Aigner E
Dig Liver Dis; 2022 Jan; 54(1):84-90. PubMed ID: 34261618
[TBL] [Abstract][Full Text] [Related]
34. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
Liu YL; Reeves HL; Burt AD; Tiniakos D; McPherson S; Leathart JB; Allison ME; Alexander GJ; Piguet AC; Anty R; Donaldson P; Aithal GP; Francque S; Van Gaal L; Clement K; Ratziu V; Dufour JF; Day CP; Daly AK; Anstee QM
Nat Commun; 2014 Jun; 5():4309. PubMed ID: 24978903
[TBL] [Abstract][Full Text] [Related]
35. Use of PNPLA3, TM6SF2, and HSD17B13 for detection of fibrosis in MASLD in the general population.
Rashu EB; Werge MP; Hetland LE; Thing M; Nabilou P; Kimer N; Junker AE; Jensen AH; Nordestgaard BG; Stender S; Gluud LL
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(7):102389. PubMed ID: 38830575
[TBL] [Abstract][Full Text] [Related]
36. Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program.
Serper M; Vujkovic M; Kaplan DE; Carr RM; Lee KM; Shao Q; Miller DR; Reaven PD; Phillips LS; O'Donnell CJ; Meigs JB; Wilson PWF; Vickers-Smith R; Kranzler HR; Justice AC; Gaziano JM; Muralidhar S; Pyarajan S; DuVall SL; Assimes TL; Lee JS; Tsao PS; Rader DJ; Damrauer SM; Lynch JA; Saleheen D; Voight BF; Chang KM;
PLoS One; 2020; 15(8):e0237430. PubMed ID: 32841307
[TBL] [Abstract][Full Text] [Related]
37. Polymorphisms Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease Influence the Progression of End-Stage Liver Disease.
Kocas-Kilicarslan ZN; Cetin Z; Faccioli LAP; Motomura T; Amirneni S; Diaz-Aragon R; Florentino RM; Sun Y; Pla-Palacin I; Xia M; Miedel MT; Kurihara T; Hu Z; Ostrowska A; Wang Z; Constantine R; Li A; Taylor DL; Behari J; Soto-Gutierrez A; Tafaleng EN
Gastro Hep Adv; 2024; 3(1):67-77. PubMed ID: 38292457
[TBL] [Abstract][Full Text] [Related]
38. Association of glucokinase regulatory gene polymorphisms with risk and severity of non-alcoholic fatty liver disease: an interaction study with adiponutrin gene.
Tan HL; Zain SM; Mohamed R; Rampal S; Chin KF; Basu RC; Cheah PL; Mahadeva S; Mohamed Z
J Gastroenterol; 2014 Jun; 49(6):1056-64. PubMed ID: 23800943
[TBL] [Abstract][Full Text] [Related]
39. The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis.
Mederacke YS; Kirstein MM; Großhennig A; Marhenke S; Metzler F; Manns MP; Vogel A; Mederacke I
Aliment Pharmacol Ther; 2020 Jun; 51(11):1160-1168. PubMed ID: 32323349
[TBL] [Abstract][Full Text] [Related]
40. No association of NAFLD-related polymorphisms in PNPLA3 and TM6SF2 with all-cause and cardiovascular mortality in an Austrian population study.
Semmler G; Balcar L; Wernly S; Datz L; Semmler M; Rosenstatter L; Stickel F; Aigner E; Wernly B; Datz C
Wien Klin Wochenschr; 2024 May; 136(9-10):251-257. PubMed ID: 37103556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
